NeuroBo Q3 net loss $5.7M, cash $21.7M; positive Phase 1 SAD data for obesity drug DA-1726

MetaVia Inc.

2024-Q3 EPS reported -$3.24

Net loss of $5.7M (EPS -$0.55) for Q3 2024 vs. $3.8M net loss ($0.75 per share) in Q3 2023.
Cash at Sept 30, 2024: $21.7M; expected to fund operations into Q3 2025.
Positive top-line data from SAD Part 1 of Phase 1 trial for DA-1726: safe, tolerable, dose-linear PK; additional cohorts exploring MTD.
DA-1241 Phase 2a MASH trial: top-line data expected in December 2024.
Entered joint research agreement with Dong-A ST and ImmunoForge for once-monthly formulation of DA-1726.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.